How to take Asciminib

For patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) chronic phase (CP) who have received two or more TKI treatments in the past The recommended dose of Asciminib is 80 mg taken orally once daily at about the same time each day, or 40 mg taken orally twice daily about 12 hours apart. Continue treatment withaceminias long as clinical benefit is observed or unacceptable toxicity occurs. For Ph+CML-CP patients with T315I mutation: The recommended dose of aximinib is 200 mg orally twice daily.

The recommended dose of aximinib is to be taken by mouth without food. Avoid eating at least 2 hours before and at least 1 hour after taking aximinib. Patients swallow aceminib tablets whole and do not break, crush, or chew the tablets. If a patient experiences adverse reactions while taking aximinib, the doctor may reduce, interrupt, or stop the use of the drug. For Ph+CML-CP patients who have received two or more TKI treatments in the past, the initial dose of Asiminib is reduced to 40 mg orally once a day or 20 mg twice a day. Patients who cannot tolerate this dose should permanently discontinue Asiminib. For Ph+CML-CP patients with T315I mutation: The initial dose of Asiminib is reduced to 160 mg orally twice daily. Patients who cannot tolerate this dose should permanently discontinue Asiminib.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in medical insurance. The original drug of Asiminib currently sold overseas is very expensive. Generic drugs of Asiminil are also produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rate effects), and the price is relatively cheap. For more drug information and specific prices, please consult Yaode’s medical consultant.